A downtrend has been apparent in 89BIO (ETNB) lately. While the stock has lost 11.1% over the past week, it could witness a ...

Bio Inc (ETNB) has disclosed a new risk, in the Demand category. 89Bio Inc. faces a significant risk if the market ...

UBS raised the firm’s price target on 89bio (ETNB) to $38 from $25 and keeps a Buy rating on the shares. Akero Therapeutics (AKRO) reported ...

(NASDAQ:ETNB – Get Free Report)‘s stock had its “sell (d-)” rating reiterated by stock analysts at Weiss Ratings in a research report issued on Friday,Weiss Ratings reports. Several other brokerages ...

SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and ...

89bio announced a public offering of 21.67 million shares at $8.75 each, aiming for $250 million in gross proceeds. The company's reliance on an upsized public offering may indicate a need for ...

New York State Common Retirement Fund increased its stake in shares of 89bio, Inc. (NASDAQ:ETNB – Free Report) by 24.3% in ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on 89bio (ETNB – Research Report) yesterday and set a price target of $33.00. The ...

“2024 marks a tremendous year of execution and progress for 89bio, highlighted by the initiation of two global pivotal trials targeting advanced MASH patients, as well as completion of ...

The average of price targets set by Wall Street analysts indicates a potential upside of 171.4% in 89BIO (ETNB). While the effectiveness of this highly sought-after metric is questionable, the ...